Net loss for the fourth quarter of 2025 was $33.0 million, or $0.30 per share, an improvement from a net loss of $37.5 million, or $0.55 per share, for the same period in 2024. Full year 2025 net loss significantly decreased to $144.7 million, or $1.53 per share, compared to a net loss of $301.7 million, or $4.43 per share, for the full year 2024. Research and development expenses for the full year 2025 were $90.4 million, down from $104.1 million in 2024, primarily due to decreased spending on AMX0035, partially offset by increased investment in avexitide's clinical development. Selling, general, and administrative expenses for the full year 2025 were $62.9 million, a substantial decrease from $114.3 million in 2024, mainly attributed to reduced consulting and professional services. Cash, cash equivalents, and short-term investments totaled $317.0 million as of December 31, 2025, with a projected cash runway expected to fund operations into 2028. Recruitment for the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) is complete, with randomization and dosing of the last eligible participants expected in March 2026 and topline data anticipated in Q3 2026. AMX0318, a novel glucagon-like peptide-1 (GLP-1) receptor antagonist, was selected as a development candidate for PBH and other rare diseases, with an Investigational New Drug (IND) filing targeted for 2027. Early safety and tolerability data from Cohort 1 of the Phase 1 LUMINA trial of AMX0114 in ALS were presented in December 2025, showing the investigational antisense oligonucleotide (ASO) was generally well-tolerated with no treatment-related serious adverse events (SAEs).